Biotech/Pharma

Allergic rhinoconjunctivitis affects more than 500 million people worldwide, with children facing particular challenges including sleep disruption, missed school days, and increased asthma risk. Stallergenes Greer announced that its Phase IIIb clinical study for Staloral Birch, a sublingual allergen immunotherapy, […]

Prenatal testing for inherited genetic conditions typically requires invasive procedures that carry some risk to the pregnancy. Natera announced it will expand its Fetal Focus noninvasive test from five genes to 20 genes, with plans to launch the expanded panel

Patients with metastatic lung cancer and low PD-L1 expression face limited targeted treatment options in the first-line setting, with current standard care relying on immunotherapy combined with traditional chemotherapy. Daiichi Sankyo and AstraZeneca have initiated the DESTINY-Lung06 phase 3 trial,

As mental health treatment developers seek funding to advance clinical programs through late-stage trials, psychedelic medicine companies face particular scrutiny over their path to commercialization. Cybin Inc., a Toronto-based neuropsychiatry company, recently closed a $175 million registered direct offering to

Sepsis causes 48.9 million cases and 11 million deaths worldwide each year, accounting for approximately one in five of all global deaths. ABIONYX Pharma recently announced that a study published in Scientific Reports provides genetic evidence linking apolipoprotein A-I (ApoA-I)

A telehealth company has announced a celebrity partnership to promote conversations about medical weight management. Ro, a direct-to-patient healthcare company, announced that 23-time Grand Slam champion Serena Williams has been using their platform to access GLP-1 medications and will serve